Glyceryl trinitrate in first-episode psychosis unmedicated with antipsychotics: A randomised controlled pilot study

Kate Merritt1,2*, Ana Catalan1,3,4, Samuel Cowley1, Arsime Demjaha1, Matthew Taylor1,5*, Philip McGuire4, Ruth Cooper6,7* and Paul Morrison1*

Abstract

Background: There is a pressing need for new classes of treatment for psychosis. A key therapeutic target for novel compounds is the NMDA receptor, which may be modulated by nitric oxide donors such as sodium nitroprusside (SNP). Recent studies of SNP in patients with psychosis have mixed results, and the drug has to be administered intravenously. Glyceryl trinitrate (GTN) is a well-established cardiovascular medicine that is also a nitric oxide donor, and can be given orally.

Methods: This was a single-centre, randomised, double-blind, placebo-controlled trial from December 2016 to April 2019 (ClinicalTrials.gov identifier: NCT02906553). Patients received 3 sprays of GTN or placebo for three consecutive days, and were re-assessed on Days 1, 2, 3 and 7. The primary outcome was cognition (Jumping to Conclusions task), secondary outcomes were symptoms (Positive and Negative Syndrome Scale (PANSS)), verbal memory (Hopkins Verbal Learning task), and mood (Bond–Lader Visual Analogue Scales).

Results: Nineteen patients were randomised, and 13 participants were included in the analyses. Compared with placebo, GTN was well tolerated, but was not associated with significant effects on cognition, symptoms, or mood. Bayesian statistics indicate that our results were 2× more likely under the null hypothesis than the alternative hypothesis, providing anecdotal evidence that GTN does not improve psychotic symptoms.

Conclusions: We found no indication of an effect of GTN on symptoms of psychosis or cognition.

Keywords
Clinical trial, psychosis, schizophrenia, sodium nitroprusside, glyceryl trinitrate

Introduction

Antipsychotic medications blocking the dopamine D2 receptor are the first-line treatment for psychosis (Leucht et al., 2012a). These medicines are effective in reducing symptoms and risk of relapse (Leucht et al., 2012b), but are ineffective in around a third of patients and have little impact on negative symptoms and cognitive deficits (Samara et al., 2019). Moreover, their use is associated with adverse effects including weight gain and diabetes (De Hert et al., 2012; Rummel-Kluge et al., 2010). There is thus a pressing need for new classes of treatment.

Nitric oxide donors are a candidate medicine targeting the NMDA receptor for glutamate, the function of which is thought to be altered in psychosis (Javitt and Zukin, 1991; Ripke et al., 2014), indicated by elevated brain glutamate levels in patients with psychosis (Merritt et al., 2016). Nitric oxide acts as a gaseous second messenger which activates guanylate cyclase in the brain. One downstream effect of this is the modulation of NMDA receptor activity (Hoyt et al., 1992; Manzoni et al., 1992; Pitsikas, 2015). Preclinical studies report that sodium nitroprusside (SNP, a nitric oxide donor) blocks the effects of an NMDA receptor antagonist in rats, suggesting that nitric oxide donors may be therapeutically beneficial in psychosis (Bujas-Bobanovic et al., 2000).

In 2013, Hallak and colleagues reported that SNP, delivered intravenously as an adjunct to antipsychotic medication, was effective in reducing acute psychotic symptoms in patients in the early phase of psychosis (Hallak et al., 2013a). However, subsequent studies in patients with chronic schizophrenia have not replicated this finding (Brown et al., 2019; Stone et al., 2016; Wang et al., 2018). It has been argued that SNP may only be effective in the early phases of psychosis in patients who have received relatively little antipsychotic treatment (Maia-De-Oliveira et al., 2017). This would be consistent with neuroimaging evidence that...
brain glutamate dysfunction in psychosis varies with stage of illness (Merritt et al., 2016), and preclinical data showing that novel compounds that act on glutamate/GABA function are only effective in rodents that have not been exposed to D2 receptor antagonists (Gill et al., 2014).

In previous trials, SNP was tested as an adjunct to antipsychotic medication, with the placebo-control condition consisting of patients receiving placebo in addition to antipsychotic medication. All trials showed an improvement in symptoms with SNP + an adjunct antipsychotic; however, the three negative trials also reported a significant improvement in symptoms for the placebo arm (those receiving placebo + antipsychotic) (Brown et al., 2019; Stone et al., 2016; Wang et al., 2018). Therefore, the efficacy of SNP may be masked by the response to the existing antipsychotic, and so there is a need to test nitric oxide donors in patients unmedicated with antipsychotics to determine its true efficacy.

The administration of SNP is logistically difficult, as it requires an intravenous infusion. Glycerol trinitrate (GTN) has the same mechanism of action as SNP, by rapid breakdown to nitric oxide. However, GTN can be administered sub-lingually and as such could be more feasible in a psychiatric setting. Therefore, the present study aimed to investigate the safety and feasibility of conducting a trial of GTN in unmedicated patients experiencing an acute first episode of psychosis, and whether GTN could potentially be effective in reducing psychotic symptoms and improving cognition.

Methods

Trial design

The Nitric Oxide in Cognition Study was a single-site, 1 week, double-blind, randomised, placebo-controlled pilot study of GTN spray (ClinicalTrials.gov identifier: NCT02906553). The study was conducted at the Institute of Psychiatry, Psychology and Neuroscience, London, UK. Ethical approval was obtained from the London Bromley Research Ethics Committee (16/LO/1102), and the study adhered to the Declaration of Helsinki.

Participants

Between December 2016 and April 2019, 602 adults were assessed for eligibility (Figure 1). Participants were recruited from inpatient wards and community mental health teams within the South London & Maudsley Trust, alongside Participant Identification Centres in Central and North West London and East London NHS Foundation Trusts. Informed, written consent was obtained from all subjects. Capacity was assessed by the researcher and treating clinicians. Participants were asked to state the aim of the study and what it involved in their own words to ensure understanding. Inclusion and exclusion criteria are listed in Table 1.

Interventions

Participants received the maximum recommended dose of GTN: 3 × sprays of 400 µg per metered dose of active treatment (GTN & <100 mg ethanol per spray, Pharmasol Ltd, North Way), or the inactive placebo (96% ethanol, Pharmasol Ltd, North Way) for three consecutive days (Day 1, Day 2, Day 3). Drug administration was observed by the researcher (KM), and the spray was self-administered, sub-lingually. Study medication was prescribed by the study doctor (PM), and stored and dispensed by the Maudsley Hospital pharmacy. As headache is a common side effect of GTN, participants were asked if they wished to receive pre-treatment paracetamol (1 g) and ibuprofen (400 mg). The bioavailability of GTN following sublingual administration is ~40%. Plasma concentrations peak after ~3 min, biologically active metabolites have a half-life of approximately 40 min and it exerts a duration of action of ~25 min for cardiovascular effects (Divakaran and Loscalzo, 2017). In comparison, Hallak et al. administered a low dose of IV SNP (0.5 µg/kg/min) which has 100% bioavailability (Hallak et al., 2013b).

Assessments

Visits took place on the ward, or at the Clinical Research Facility based at King’s College Hospital. Testing sessions occurred at five different time-points (carried out by KM): baseline (pre-dose), assessment 1 (day 1 following treatment), assessment 2 (day 2 following treatment), assessment 3 (day 3 following treatment) and assessment 4 (day 7 no treatment). Outcome measures were conducted 30 min post-dose, following the typical duration of action of GTN for cardiovascular effects and half-life of active metabolites (Divakaran and Loscalzo, 2017).

Outcomes

The following outcomes were measured at all assessments: (a) the emotionally salient version of the Jumping to Conclusions (JTC) task (Menon et al., 2006), (b) the Hopkins Verbal Learning Task – Revised (HVLT) (Shapiro et al., 1999), (c) Positive and Negative Syndrome Scale (PANSS) (videotaped) (Kay et al., 1987), (d) the Bond–Lader Visual Analogue Scales (Bond and Lader, 1974), (e) safety measures: side effects, blood pressure and heart rate. Demographic and recreational drug use data (historical use and Cannabis Experiences Questionnaire) were collected at baseline.

The primary outcome was the emotionally salient version of the JTC task, a version of the beads task, which was used to test the cognitive underpinnings of delusions. Performance on the JTC task improves with D2 receptor antipsychotic treatment (Menon et al., 2008). In the task, jumping to conclusions is defined as a draw score of less than 3 (Garety et al., 2013).

In the computerised JTC task (Psychopy V3.1.4), participants are presented with a scenario where a character ‘Jack’ is in court facing charges for crashing into a car. A solicitor has conducted a survey on 100 people from Jack’s community, asking them to provide one word to describe Jack, to determine how well liked he is. Participants are informed that Jack is either mostly liked (60% said good words and 40% said bad words about Jack), or mostly disliked (40% said good words and 60% said bad words about Jack). Participants view the one-word opinions from the survey, one word at a time, and must select whether to view another word, or decide whether Jack was mostly liked or disliked. All previously viewed words appear on the bottom of the screen to eliminate working
memory load. Up to 15 words can be viewed in total. Participants are instructed to select the finish button when they have viewed enough words to decide whether Jack was mostly liked or disliked, and are then prompted to enter their decision. The outcome measure is the number of words (‘opinions’) viewed, averaged over three trials. Participants repeat the JTC task three times each visit, with the same scenario using a different word list in a predetermined random order.

Secondary outcomes included: the PANSS assessment, the HVLT task, and the Bond–Lader Visual Analogue Scales. KM

---

**Table 1.** Inclusion and exclusion criteria.

| Inclusion Criteria                                                                 | Exclusion Criteria                                      |
|-----------------------------------------------------------------------------------|---------------------------------------------------------|
| Patients undergoing an acute psychotic episode; defined as score ≥4 on question   | Prior history of intolerance to glyceryl trinitrate      |
| P1 Delusions or P3 Hallucinatory behaviour of the PANSS positive subscale         | Systolic blood pressure below 90mmHg, heart             |
| Under clinical care of community early intervention team or ward                  | rate above 100bpm                                       |
| Capacity to give consent                                                          | Any major physical illness                              |
| 18–45 years of age                                                                | Homicidal or suicidal                                   |
| Currently unmedicated with antipsychotic medication                               | Pregnant or breast feeding                               |
conducted videotaped PANSS assessments with participants, from which the PANSS were scored by both the researcher (KM) and psychiatrist (AC). Discrepancies were discussed and final scores were reached by consensus. For the HVLT task, participants recall a list of 12 words read aloud to them. This is repeated a total of three times with the same word list, and 20–25 min later participants are asked to recall the word list. Immediate recall scores were averaged across the three recall conditions, and the delayed recall score was collected at each visit. Different word lists were used at each visit. The Bond–Lader Visual Analogue Scales consist of 16, 10 cm visual analogue scales which ask participants to rate their current mood (Bond and Lader, 1974). Scores are calculated for the following categories: alertness, calmness, and contentedness.

Sample size

As this was a pilot study formal power calculations are not required (Eldridge et al., 2016). In line with pilot study guidance recommending 30–55 participants (Lancaster et al., 2004), we initially intended to recruit 36 patients.

Randomisation and blinding

Randomisation was carried out by an independent member of staff in the King’s Clinical Trial Unit using a bespoke web-based dynamic randomisation service, using block randomisation of varying sizes (2 and 4) stratified by whether participants had previously been treated with antipsychotic medication (yes/no). Treatment arm allocation emails were automatically sent to the Maudsley Hospital pharmacy where the medication was labelled and blinded before being dispensed. Researchers did not have access to the randomisation list, and a 24/7 emergency unblinding service was available from the pharmacy. Both investigators and participants were blind to treatment allocation. The placebo and active treatments were identical in appearance, taste and method of administration. On day 7, participants were asked which group they thought they were allocated to, to assess the maintenance of the blind.

Analysis

Bayesian statistics investigated the effect of GTN on positive PANSS score. The traditional p-value approach is able to disprove the null hypothesis (that there is no beneficial effect of GTN for psychotic symptoms); however, it does not allow us to infer whether there is enough evidence to support the null hypothesis (Quintana and Williams, 2018). To determine whether the data favour the null hypothesis compared with the alternative hypothesis (that GTN reduces psychotic symptoms), we conducted a Bayesian one-tailed independent samples t-test (Dienes, 2014; Jeffreys, 1998). Bayesian statistics were conducted using JASP (JASP Team, 2019), comparing slope values (change in PANSS positive score from baseline to Day 3, and baseline to Day 7) between treatment arms. The Cauchy prior was set according to the maximum effect size detectable versus placebo in the current study, based on the maximum possible improvement from baseline PANSS symptom score, average placebo response, and standard deviation of the change in score for each group. JASP compares this alternative model to a model of the null hypothesis set at an effect size of 0. Hedges g effect sizes are reported (’effsize’ package on ‘R’ (v0.7.6, Torchiano)). Due to the small sample size of the study, frequentist statistical analyses (repeated measures ANOVA) of PANSS positive scores and JTC task responses are included in the supplemental material only, alongside a figure of the drug–placebo response curve (Farace et al., 2000). Two-sample t-tests assessed differences in demographic and clinical factors between treatment groups at baseline, and repeated measures ANOVA assessed change in blood pressure and heart rate (SPSS version 24, SPSS inc. Chicago, IL, USA). Graphs were produced using the package ggplot2 (Wickham, 2009) within R 3.6 (R Core Team, 2014). The data that support the findings of this study are available from the corresponding author upon reasonable request.

Results

Participant flow and recruitment

In total, 19 participants were randomised, eight participants received GTN and seven participants received placebo. Four dropped out after baseline and did not receive an intervention: three declined further participation, and one was too unwell to continue (Figure 1). At follow-up a further two participants dropped out from the GTN arm; one requested withdrawal of all their data from study (no reason was given), and one was discharged from the ward and no longer wanted to take part (participant not included in intent-to-treat analysis as review of PANSS videotapes concluded that participant did not meet inclusion criteria for symptom severity). The final analysis included six participants in the GTN arm, and seven in the placebo arm.

After participation in the study, it emerged that one participant in the GTN arm had been prescribed olanzapine 10 mg and a monthly haloperidol 75 mg depot injection. Although this patient did not meet inclusion criteria of being unmedicated with antipsychotic medication, sensitivity analyses indicated that their inclusion did not change the results. No other participants were receiving antipsychotic medication at baseline: nine were antipsychotic naïve, and three reported previous antipsychotic treatment prior to the study. Of the latter, one received 5 mg olanzapine for 1 day, 4 days prior to baseline; one received chlorpromazine for 5 days, 4 years prior to baseline; and one participant received aripiprazole intermittently for 1.5 years, 4 months prior to baseline. For nine participants this was their first contact with a psychiatric ward or early intervention community team. During the study, one participant was started on 10 mg aripiprazole on Day 3, and one participant was started on 0.5 mg risperidone on Day 5.

Primary and secondary outcomes

At baseline there were no significant differences in demographics or any of the primary and secondary outcomes between the GTN and placebo treatment groups (Table 2).

To determine whether the data favoured the null hypothesis (that there is no beneficial effect of GTN on psychotic symptoms) compared with the alternative hypothesis (that GTN
reduces psychotic symptoms), we conducted Bayesian independent samples \( t \)-tests. Repeated measures ANOVA results are included in the Supplemental information.

For the change in PANSS positive score from baseline to Day 3 (treatment days only), the maximum effect size detectable (versus placebo) was \( d = 2.1 \). The Cauchy prior distribution was centred around 0.5 (the therapeutic effect of newer atypical antipsychotics (Leucht et al., 2009)). The resulting Bayes Factor (BF\(+0\)) was 0.445 (CI 0.025–1.058), indicating anecdotal evidence in favour of the null hypothesis that GTN has no beneficial effect on psychotic symptoms, as the data are 2.2 \( \times \) more likely under the null (H0) than the alternative hypothesis (H1). The magnitude of the effect size between groups (change in PANSS positive score from baseline to Day 3) was negligible; Hedges \( g = 0.18 \) (CI −0.96 to 1.32).

For the change in PANSS positive score from baseline to Day 7 (final follow-up without treatment), the maximum detectable effect size was \( d = 0.7 \) (smaller effect size due to larger placebo response on Day 7). The Cauchy prior distribution centred around 0.35 with a scale parameter of 0.12, corresponding to a probability of 80% that the effect size lies between 0 and 0.70. We found a Bayes Factor (BF\(+0\)) of 0.468 (CI 0.035–0.634), indicating anecdotal evidence in favour of the null hypothesis that GTN has no beneficial effect on psychotic symptoms, as the data are 2.1 \( \times \) more likely under the null (H0) than the alternative hypothesis (H1). The reduction in PANSS positive symptoms between baseline and Day 7 was greater in the placebo group compared with the GTN group; Hedges \( g = 0.68 \) (CI −0.49 to 1.84, Figure 2).

For the JTC task, only one participant demonstrated jumping to conclusions at baseline by viewing three or fewer words (Figure 2). Therefore Bayesian analyses to determine whether participants in the GTN group viewed more words over time are not applicable.

40% of patients in the GTN group correctly guessed that they received GTN and 71% in the placebo group correctly guessed they received placebo, indicating that patients were not unblinded during the study.

---

### Table 2. Baseline demographics and clinical characteristics of participants.

|                      | GTN \( n=6 \) Mean (SD) | Placebo \( n=7 \) Mean (SD) |
|----------------------|--------------------------|-------------------------------|
| **Age (years)**      | 23.8 (7.1)               | 25.4 (6.8)                    |
| **Male/Female**      | 6/0                      | 5/2                           |
| **Education, years beyond 16** | 1.8 (1.6)               | 2.3 (1.5)                     |
| **Currently employed Y/N/Student** | 0/3/3                   | 0/5/2                         |
| **Ethnicity (White/Black/Asian/Mixed race)** | 2/2/1/1                 | 1/3/1/2                       |
| **Previously treated with antipsychotic medication Y/N** | 2/4                     | 1/6                           |
| **Antipsychotic medication at Day 0 Y/N** | 1/5                     | 0/7                           |
| **Antipsychotic medication at Day 3 Y/N** | 2/4                     | 0/7                           |
| **Antipsychotic medication at Day 7 Y/N** | 2/4                     | 1/6                           |
| **Promethazine at Day 0 Y/N** | 0/6                     | 0/7                           |
| **Promethazine at Day 3 Y/N** | 0/6                     | 2/5                           |
| **Promethazine at Day 7 Y/N** | 0/6                     | 1/6                           |
| **Benzodiazepine/Zopiclone at Day 0 Y/N** | 1/5                     | 2/5                           |
| **Benzodiazepine/Zopiclone at Day 3 Y/N** | 1/5                     | 2/5                           |
| **Benzodiazepine/Zopiclone at Day 7 Y/N** | 1/5                     | 1/6                           |
| **Current smoker or receiving NRT Y/N** | 3/3                     | 4/3                           |
| **Cannabis use Never / >1 year / >1 m / Last month** | 1/0/1/4                | 0/2/1/4                       |
| **Other recreational drugs Never / >1 year / >6 m / Last month** | 3/0/0/3                | 2/2/1/2                       |
| **Patient correct regarding Trial Arm Y/N** | 2/3 \( n=5 \)         | 5/7                           |

**Primary outcome**

| Number of draws on JTC task (Day 0) | 10.8 (5.3) | 14.4 (1.1) |

**Secondary outcomes**

| PANSS Positive (Day 0) | 21.5 (3.7) | 19.1 (4.1) |
| PANSS Negative (Day 0) | 10.2 (2.8) | 11.7 (2.9) |
| PANSS General (Day 0)  | 29.0 (5.6) | 33.6 (4.9) |
| PANSS Total (Day 0)    | 60.7 (7.8) | 64.4 (8.8) |
| Mean learning trial recall HVLT (Day 0) | 6.9 (1.5) | 7.9 (2.6) |
| Delayed recall HVLT (Day 0) | 7.2 (3.4) | 7.4 (3.0) |
| Mood scale Alert (Day 0) | 22.2 (14.5) | 31.7 (6.1) |
| Mood scale Content (Day 0) | 14.8 (8.6) | 19.8 (1.5) |
| Mood scale Calm (Day 0) | 5.1 (2.7) | 6.1 (0.9) |

There were no significant differences between GTN and Placebo treatment groups at baseline (Day 0). PANSS: Positive and Negative Syndrome Scale; higher scores indicate more severe symptom severity. HVLT: Hopkins Verbal Learning Test. Lower scores on mood scales indicate higher alertness, etc. NRT: nicotine replacement therapy.
Figure 2. (a) Individual patient PANSS positive scores plotted over time. The change in PANSS positive score over time did not differ between treatment groups. Graphs are split based on treatment arm; the left panel shows patients receiving placebo, the right panel shows patients receiving GTN. (b) Number of words viewed by each participant during the JTC task over time (mean of three trials on each day). Only one participant demonstrated jumping to conclusions by viewing three or fewer words at baseline. Group mean at each visit is shown in black, grey ribbon indicates between-subjects standard error.

Safety measures

There were no serious adverse events and GTN was well tolerated. Reported side effects in the GTN group included dizziness (n=2), stinging sensation in mouth (n=1), nosebleed (n=1), fatigue (n=1) and headache (n=1). There was no significant difference in the number of side effects reported between the GTN and placebo treatment arms. GTN did not affect systolic or diastolic blood pressure (Table 3), but was associated with an increased heart rate (repeated measures ANOVA of change in heart rate pre and post drug, significant effect of group (F(1,9)=6.689, p=0.029, ηp²=0.426).

Discussion

This is the first study to investigate the feasibility and potential effects of GTN in patients with psychosis. We did not find any evidence of an effect of GTN over placebo on psychotic symptoms or cognitive performance. We demonstrated that GTN was well tolerated, with minimal side effects, and no effect on systolic or diastolic blood pressure, but an increase in heart rate.

Our results are consistent with data from recent studies of SNP in psychosis, which found no effect on symptoms or on spatial working memory (Brown et al., 2019; Stone et al., 2016; Wang et al., 2018), but not those from the first study of SNP in psychosis, which reported improvements in both positive and negative symptoms of psychosis (Hallak et al., 2013a). The former studies examined chronic patients who were receiving treatment with antipsychotic medication, and one explanation for the difference in their results compared with those from the first study is that it involved first-episode patients (Gill et al., 2014; Stone, 2011). This was a key driver for us investigating another nitric oxide donor in first-episode psychosis rather than chronic patients.

There was a significant reduction in psychotic symptoms over time, and a small but significant improvement on the HVLT immediate and delayed recall. This resulted in a large placebo response in our cohort, limiting the power of the study, alongside a small sample size. Bayesian statistics indicated that our results were 2× more likely under the null hypothesis than the alternative hypothesis, providing anecdotal evidence that GTN does not have a therapeutic effect at the magnitude seen with newer atypical antipsychotics (Leucht et al., 2009). Due to the small sample...
size and large confidence intervals of the Bayes Factors, these results should be taken with a degree of uncertainty. The 41% reduction in PANSS positive scores for the placebo group, and 16% reduction for the GTN group does not meet clinical significance for the majority of patients, although three patients were classified as borderline or no longer mentally unwell at the end of the study. This was the first contact with mental health services for the majority of patients, and so reinforces the value of an initial antipsychotic-free observation period. This initial assessment period where patients remain free of antipsychotic medication when first presenting with an episode of psychosis provided a suitable opportunity to recruit unmedicated patients into our study. A limitation of this approach, however, is that definitive diagnoses are not typically made during the first episode of psychosis.

Patients in the current sample did not demonstrate a ‘jumping to conclusions’ reasoning bias (defined as a word draw of less than three, whereas the mean word draw at baseline was 13), and so it was difficult to assess improvement on this task. This is in contrast to previous reports of a lower number of draws needed to reach a decision in patients with schizophrenia (McLean et al., 2016). We used an emotionally salient version of the task, performance on which has been shown to normalise following antipsychotic treatment (Menon et al., 2008). The absence of a JTC reasoning bias may result from the task being computerised, as this may enforce less social pressure to make a decision earlier. Moreover the presence of a memory aid has been found to abolish the difference in performance between patients with schizophrenia and healthy volunteers (Menon et al., 2006), but not in all studies (Dudley et al., 1997), indicating that JTC bias may result from poor working memory. Patients possessed an average PANSS delusion score of 5 at baseline (‘moderate severe’) yet did not show a JTC bias, suggesting that JTC bias may not be necessary for the formation of delusions. This is consistent with previous research showing that JTC bias is not related to positive symptom severity in first-episode psychosis patients (Catalan et al., 2015).

This study highlights the significant logistical challenges in recruiting unmedicated first-episode patients. A total of 606 patients were screened, but only 19 of these were randomised. The main barrier was that the majority of patients screened for the study were thought to require immediate treatment on presentation, and were started on antipsychotic medication before they could enter the trial. It is more feasible to examine novel antipsychotics as an adjunctive to anti-dopaminergic antipsychotic treatment, although when symptom improvement occurs in both trial arms (as seen with SNP), it is difficult to interpret this result and so trials in unmedicated patients are also needed.

Moving forwards, it would be beneficial if frameworks for testing new medicines were built into clinical services, to signpost patients showing a poor response to antipsychotics (estimated as 38% of patients (Samara et al., 2019)) and those not taking antipsychotic medication (upwards of 40% of patients (Lacro et al., 2002; Lieberman, 2007)) into clinical trials of alternatives. Clinical trials recruiting unmedicated patients should include clear criteria for treating patients with antipsychotics at early signs of clinical deterioration (Morrison et al., 2018); in the present study two patients were started on antipsychotic medication when clinicians deemed this necessary. The length of time needed to administer the experimental treatment should also be considered; a longer treatment period increases the confidence of detecting a treatment effect, but the amount of time not receiving treatment as usual should be minimised. In the present study we administered GTN for 3 days, whereas a longer duration of treatment may be necessary for efficacy. A shorter trial duration may also reduce drop out in the placebo group, which was low in the present study (n=0 discontinuation in placebo arm), but is common in placebo-controlled trials of antipsychotics (Fleischhacker et al., 2003). Future studies would benefit from using a sequential parallel comparison design to increase statistical power by reducing placebo-response data (Ivanova et al., 2011). An alternative method is to test novel drugs in participants at an ultra-high risk of schizophrenia. This population is not generally treated with antipsychotics as an adjunctive to anti-dopaminergic antipsychotic treatment, although when symptom improvement occurs in both trial arms (as seen with SNP), it is difficult to interpret this result and so trials in unmedicated patients are also needed.

Moving forwards, it would be beneficial if frameworks for testing new medicines were built into clinical services, to signpost patients showing a poor response to antipsychotics (estimated as 38% of patients (Samara et al., 2019)) and those not taking antipsychotic medication (upwards of 40% of patients (Lacro et al., 2002; Lieberman, 2007)) into clinical trials of alternatives. Clinical trials recruiting unmedicated patients should include clear criteria for treating patients with antipsychotics at early signs of clinical deterioration (Morrison et al., 2018); in the present study two patients were started on antipsychotic medication when clinicians deemed this necessary. The length of time needed to administer the experimental treatment should also be considered; a longer treatment period increases the confidence of detecting a treatment effect, but the amount of time not receiving treatment as usual should be minimised. In the present study we administered GTN for 3 days, whereas a longer duration of treatment may be necessary for efficacy. A shorter trial duration may also reduce drop out in the placebo group, which was low in the present study (n=0 discontinuation in placebo arm), but is common in placebo-controlled trials of antipsychotics (Fleischhacker et al., 2003). Future studies would benefit from using a sequential parallel comparison design to increase statistical power by reducing placebo-response data (Ivanova et al., 2011). An alternative method is to test novel drugs in participants at an ultra-high risk of schizophrenia. This population is not generally treated with antipsychotics, and so their involvement in clinical trials does not deny these patients of standard treatment.

It should be noted that GTN is a short-acting medication, and its ability to cross the blood–brain barrier has not been ascertained. Future studies of novel medicines should assess the drugs bioavailability in the brain through neuroimaging studies. Furthermore, novel medicines with glutamatergic targets should select patients with elevated brain glutamate levels, as determined by 1H-MRS scans (Egerton, 2019).

The results from our study show no indication of an effect of GTN on symptoms of psychosis or on cognition, and highlights the difficulties in recruiting unmedicated patients. These results,
along with the largely negative findings for SNP, suggest there is little evidence that nitric oxide represents a novel target that will yield a new class of antipsychotic drug.

Acknowledgements

We would like to principally thank the patients who took part in our study, and to the community and ward teams involved in the study, with particular thanks to the LEO ward and ES2 ward. Many thanks to the doctors whose help was invaluable, including Dr Thomas Reilly, Dr Sameer Jauhar, Dr Anil Kumar, Dr Jessica Ball, Dr Jessica Fletcher-Rogers, Dr Lucy Harbrow, Dr Nikhil Sharma, Dr Stewart D’Arch Smith, Dr Nwoarima Kamalu, Dr Faiza Mufti, Dr Edward Chesney, Dr Luke Jelen, Dr Christopher Linden, Dr Tom Spencer, Dr Rashmi Patel, Dr Benjamin Spencer and Dr David McLaughlan.

Author Contributions

RC, PM, and MT conceived and designed the study. All authors made substantial contributions to the data collection, analysis or interpretation. KM drafted the manuscript which was critically reviewed by all authors. All authors have approved the final version of the paper and agree to be accountable for all aspects of the work.

Declaration of conflicting interests

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: MT reports personal fees from Lundbeck, Sunovion, and Otsuka, outside the submitted work. KM, AC, SC, AD, PM, RC and PM declare no conflicts of interest.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was funded by Guys & St Thomas’ Charity grant (EFT150704) awarded to PM. The research was supported by the Department of Health via the National Institute for Health Research (NIHR) Specialist Biomedical Research Centre for Mental Health award to South London and Maudsley NHS Foundation Trust (SLaM) and the Institute of Psychiatry at King’s College London, London.

ORCID iDs

Kate Merritt https://orcid.org/0000-0002-5716-4941
Matthew Taylor https://orcid.org/0000-0003-4716-4662

Supplemental material

Supplemental material for this article is available online.

References

Bond A and Lader M (1974) The use of analogue scales in rating subjective feelings. Br J Clin Psychol 47: 211–218.

Brown HE, Freudereich O, Fan X, et al. (2019) Efficacy and tolerability of adjunctive intravenous sodium nitroprusside treatment for outpatients with schizophrenia. JAMA Psychiatry 76: 691–699.

Bujas-Bobanovic M, Bird DC, Robertson HA, et al. (2000) Blockade of phencyclidine-induced effects by a nitric oxide donor. Br J Pharmacol 130: 1005–1012.

Catalan A, Simons CJ, Bustamante S, et al. (2015) Data gathering bias: Trait vulnerability to psychotic symptoms? PLoS One 10: e0132442.

De Hert M, Detraux J, van Winkel R, et al. (2012) Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 8: 114–126.

Dienes Z (2014) Using Bayes to get the most out of non-significant results. Front Psychol 5: 781.

Divakaran S and Loscalzo J (2017) The role of nitroglycerin and other nitrogen oxides in cardiovascular therapeutics. J Am Coll Cardiol 70: 2393–2410.

Dudley RE, John CH, Young AW, et al. (1997) Normal and abnormal reasoning in people with delusions. Br J Clin Psychol 36: 243–258.

Egerton A (2019) The potential of 1H-MRS in CNS drug development. Psychopharmacology (Berl). Epub ahead of print 5 September 2019. DOI: 10.1007/s00213-019-05344-7.

Eldridge SM, Chan CL, Campbell MJ, et al. (2016) CONSORT 2010 statement: Extension to randomised pilot and feasibility trials. Pilot Feasibility Stud 2: 64.

Faraone SV, Biederman J, Spencer TJ, et al. (2000) The drug-placebo response curve: A new method for assessing drug effects in clinical trials. J Clin Psychopharmacol 20: 673–679.

Fleischhacker WW, Czobor P, Hummer M, et al. (2003) Placebo or active control trials of antipsychotic drugs? Arch Gen Psychiatry 60: 458–464.

Garety P, Joyce E, Jolley S, et al. (2013) Neuropsychological functioning and jumping to conclusions in delusions. Schizophr Res 150: 570–574.

Gill KM, Cook JM, Poe MM, et al. (2014) Prior antipsychotic drug treatment prevents response to novel antipsychotic agent in the methylazoxymethanol acetate model of schizophrenia. Schizophr Bull 40: 341–350.

Hallak JE, Maia-de-Oliveira JP, Abrao J, et al. (2013a) Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside: A randomized, double-blind, placebo-controlled trial. JAMA Psychiatry 70: 668–676.

Hallak JE, Maia-de-Oliveira JP, Abrao J, et al. (2013b) Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside: A randomized, double-blind, placebo-controlled trial. JAMA Psychiatry 70: 668–676.

Hoyt KR, Tang L-H, Aizenman E, et al. (1992) Nitric oxide modulates NMDA-induced increases in intracellular Ca2+ in cultured rat forebrain neurons. Brain Res 592: 310–316.

Ivanova A, Qaqish B and Schoenfeld DA (2011) Optimality, sample size, and power calculations for the sequential parallel comparison design. Stat Med 30: 2793–2803.

JASP Team (2019) JASP (Version 0.10.2). Available at: https://jasp-stats.org/.

Javitt DC and Zukin SR (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148: 1301–1308.

Jeffreys H (1998) Theory of Probability, Oxford: Clarendon Press.

Kay SR, Fiszbein A and Opler LA (1987) The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13: 261–276.

Lacro JP, Dunn LB, Dolder CR, et al. (2002) Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: A comprehensive review of recent literature. J Clin Psychiatry 63: 892–909.

Lancaster GA, Dodd S and Williamson PR (2004) Design and analysis of pilot studies: Recommendations for good practice. J Eval Clin Pract 10: 307–312.

Leucht S, Arbter D, Engel RR, et al. (2009) How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry 14: 429–447.

Leucht S, Hiel S, Kissling W, et al. (2012a) Putting the efficacy of psychiatric and general medicine medicine into perspective: Review of meta-analyses. Br J Psychiatry 200: 97–106.

Leucht S, Tardy M, Komossa K, et al. (2012b) Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: A systematic review and meta-analysis. Lancet 379: 2063–2071.

Lieberman JA (2007) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: Efficacy, safety and cost outcomes of CATIE and other trials. J Clin Psychiatry 68(2): e04.
Maia-De-Oliveira JP, Baker GB, Dursun SM, et al. (2017, April 1) Letter to the editor: Sodium nitroprusside for schizophrenia: Could methodological variables account for the different results obtained? *Psychol Med* 47: 981–982.

Manzoni O, Prezeau L, Desagher S, et al. (1992) Sodium nitroprusside blocks NMDA receptors via formation of ferrocyanide ions. *Neuroreport* 3: 77–80.

McLean BF, Mattiske JK and Balzan RP (2016) Association of the jumping to conclusions and evidence integration biases with delusions in psychosis: A detailed meta-analysis. *Schizophr Bull* 43: 344–354.

Menon M, Mizrahi R and Kapur S (2008) “Jumping to conclusions” and delusions in psychosis: Relationship and response to treatment. *Schizophr Res* 98: 225–231.

Menon M, Pomarol-Clotet E, McKenna PJ, et al. (2006) Probabilistic reasoning in schizophrenia: A comparison of the performance of deluded and nondeluded schizophrenic patients and exploration of possible cognitive underpinnings. *Cogn Neuropsychiatry* 11: 521–536.

Merritt K, Egerton A, Kempton MJ, et al. (2016) Nature of glutamate alterations in schizophrenia a meta-analysis of proton magnetic resonance spectroscopy studies. *JAMA Psychiatry* 73: 665–674.

Morrison AP, Law H, Carter L, et al. (2018) Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: A randomised controlled pilot and feasibility study. *Lancet Psychiatry* 5: 411–423.

Pitsikas N (2015) The role of nitric oxide donors in schizophrenia: Basic studies and clinical applications. *Eur J Pharmacol* 766: 106–113.

Quintana DS and Williams DR (2018) Bayesian alternatives for common null-hypothesis significance tests in psychiatry: A non-technical guide using JASP. *BMC Psychiatry* 18: 178.

R Core Team (2014) *R: A Language and Environment for Statistical Computing*. Vienna: R Foundation for Statistical Computing.

Ripke S, Neale BM, Corvin A, et al. (2014) Biological insights from 108 schizophrenia-associated genetic loci. *Nature* 511: 421–427.

Rummel-Kluge C, Komossa K, Schwarz S, et al. (2010) Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis. *Schizophr Res* 123: 225–233.

Samara MT, Nikolakopoulou A, Salanti G, et al. (2019) How many patients with schizophrenia do not respond to antipsychotic drugs in the short term? An analysis based on individual patient data from randomized controlled trials. *Schizophr Bull* 45: 639–646.

Shapiro AM, Benedict RH, Schretlen D, et al. (1999) Construct and concurrent validity of the Hopkins Verbal Learning Test – Revised. *Clin Neuropsychol* 13: 348–358.

Stone JM (2011) Glutamatergic antipsychotic drugs: a new dawn in the treatment of schizophrenia? *Ther Adv Psychopharmacol* 1: 5–18.

Stone JM, Morrison PD, Koychev I, et al. (2016) The effect of sodium nitroprusside on psychotic symptoms and spatial working memory in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial. *Psychol Med* 46: 3443–3450.

Wang X, Zhao J, Hu Y, et al. (2018) Sodium nitroprusside treatment for psychotic symptoms and cognitive deficits of schizophrenia: A randomized, double-blind, placebo-controlled trial. *Psychiatry Res* 269: 271–277.

Wickham H (2009) *Ggplot2: Elegant Graphics for Data Analysis*. Available at: http://ggplot2.org